Plain-English translation of NCT06306456 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing a new drug called combined with osimertinib, a medication already used to treat advanced lung cancer with EGFR mutations. Researchers want to find the safest and most effective dose of the medication, and see whether this combination works better than osimertinib alone for people whose cancer has stopped responding to previous treatments.
Some patients with this type of lung cancer eventually stop responding to standard treatments like osimertinib. This trial explores whether adding this medication to the standard treatment might help patients whose cancer has become resistant or progressed, offering a new option when current drugs no longer work.
You likely qualify if…
You likely don't qualify if…
You would take capsules of the new medication by mouth on a daily or twice-weekly schedule (depending on which group you join), combined with osimertinib taken daily. The trial has three phases that build on each other: early phases focus on finding the right dose and checking safety, while later phases test how well the combination works. You'll have regular clinic visits for blood tests, imaging scans, and check-ins with your doctor to monitor how you're doing and any side effects.
AI-generated summary from trial data · Aug 1, 2026 · Not medical advice
China